GLP-1 Medications Are Peptides: What That Actually Means

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient sat down across from me a few months ago and told me, pretty firmly, that she wasn't interested in peptide therapy. She'd read some things online, none of them flattering, and she wanted that on the record before we went any further. Then, maybe ten minutes later, she mentioned she'd been on a weekly weight loss injection for almost a year and felt better than she had in a decade.

I let it sit for a moment before saying anything. The medication she was so happy with is a peptide. It had been one the entire time.

That conversation repeats itself at Magnolia Functional Wellness more often than you'd guess. GLP-1 medications are one of the most common reasons people first walk into our Southlake office, and a good number of them believe they're taking something categorically different from "peptides," which they've filed away as fringe or unregulated or vaguely disreputable. The word has collected a lot of baggage over the past few years. Some of that baggage is deserved. But biochemistry doesn't follow marketing trends, and if you're on one of these medications, it's worth knowing what you're actually holding in your hand.

What a Peptide Actually Is

Strip away the supplement-industry noise and a peptide is a boring, specific thing: a short chain of amino acids linked together by peptide bonds. That's the whole definition. Amino acids are the building blocks your body uses to construct essentially everything, and when you string a handful of them together in a particular order, you get a peptide.

The only real difference between a peptide and a protein is length. There's no bright line, and different textbooks draw it in different places, but the working convention is that chains up to roughly 50 amino acids are peptides, and anything longer gets called a protein. Insulin is 51 amino acids, which puts it right at the border. Most people are surprised to learn insulin is a peptide hormone, but it is, and it has been since Banting and Best first isolated it in 1921. We've been treating patients with peptide medications for over a century. We just didn't market them that way.

Your body manufactures thousands of these on its own. They act as signals. A peptide hormone gets released by one tissue, travels through the bloodstream, finds a receptor on a distant cell, binds to it, and tells that cell to do something specific. Release an enzyme. Slow down. Speed up. Stop feeling hungry. The message is remarkably precise, because the shape of the peptide has to fit its receptor the way a key fits a lock.

That precision is exactly why peptides became interesting as drugs. A small molecule medication tends to wander around the body hitting a lot of targets, some of which you wanted and some of which produce the side effects listed in the fine print. A peptide that mimics one of your own signaling molecules can be far more selective about where it goes and what it does. That's the appeal, and it's also why the pharmaceutical industry has invested so heavily in this class.

Why GLP-1 Medications Sit Squarely in This Category

Glucagon-like peptide-1 is something your own gut already makes. The name gives it away. It's a 30-amino-acid peptide hormone released by cells in your small intestine when food arrives, and it does several jobs at once: it prompts your pancreas to release insulin, it slows how quickly your stomach empties, and it signals satiety centers in your brain that you've had enough.

Your natural GLP-1 works beautifully and then vanishes almost immediately. An enzyme called DPP-4 chops it apart within a couple of minutes. That rapid clearance is fine for a signal meant to fire during a meal and then go quiet, but it makes native GLP-1 useless as a medication. You'd need a continuous infusion to maintain any effect.

So the engineering problem became: how do you keep the message without the two-minute expiration date? Semaglutide is one answer. It's a modified version of the human GLP-1 sequence with a fatty acid chain attached that lets it bind to albumin in your blood, which shields it from enzymatic breakdown and stretches its half-life to about a week. Tirzepatide takes a different approach and activates two receptors instead of one, GLP-1 and GIP, which is why it's often described as a dual agonist rather than a straight GLP-1 medication.

Both are peptides. Both were designed by starting with a peptide your body already produces and asking how to make it last. When patients tell me they're "not into peptides" while pulling a weekly injection pen out of their bag, this is the disconnect I'm trying to gently close. You're not taking something exotic. You're taking a refined version of a signal your small intestine has been sending after every meal of your life.

What the Trials Actually Showed

This is where I want to be careful, because there's a meaningful difference between compounds with large randomized trials behind them and compounds without.

The STEP 1 trial, published in the New England Journal of Medicine in 2021 by Wilding and colleagues, randomized 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention. Mean body weight change at 68 weeks was about 14.9% in the treatment group versus 2.4% with placebo. You can read the full report through the STEP 1 publication on PubMed.

The following year, Jastreboff and colleagues published SURMOUNT-1 in the same journal, testing tirzepatide once weekly in 2,539 adults with obesity. At 72 weeks, participants on the highest dose saw mean weight reduction around 20.9%, with placebo at roughly 3.1%.

Those numbers get quoted constantly. The trial I find myself bringing up more often in consultations, though, is SELECT, reported by Lincoff and colleagues in the New England Journal of Medicine in late 2023. This one enrolled 17,604 patients aged 45 and up who had established cardiovascular disease and a BMI of 27 or higher, but who did not have diabetes. Over a mean follow-up near 40 months, the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke occurred in 6.5% of patients on semaglutide 2.4 mg versus 8.0% on placebo, a hazard ratio of 0.80.

That trial mattered because it moved the conversation past the scale. Roughly a 20% relative reduction in major adverse cardiovascular events, in a population that already had heart disease, is a cardiology result, not a cosmetic one. Worth noting from that same paper: about 16.6% of the semaglutide group discontinued permanently because of adverse events, compared with 8.2% on placebo. These medications are effective and they're not free of trouble. Both things are true, and any physician who only tells you the first half isn't giving you the full picture.

Wegovy and Ozempic are FDA-approved products. Semaglutide is the drug substance those products are built on. Mounjaro and Zepbound are the approved branded products built on tirzepatide.

Why "Peptide" Turned Into a Loaded Word

So if GLP-1 medications are peptides, and insulin is a peptide, why does the term make people uneasy?

Because the category is enormous, and the evidence behind different members of it varies wildly. On one end you have compounds studied in trials enrolling thousands of patients, with published cardiovascular outcome data and regulatory review. On the other end you have a long tail of compounds that have never completed human efficacy trials, aren't approved for any indication, and are sold online with confident claims that nobody has actually tested. Both get called "peptides." The word does no work at all in distinguishing between them.

It's a bit like the word "supplement," which covers both a prescription-strength vitamin D protocol your physician is monitoring with labs and a jar of something with a shirtless man on the label. The category name tells you almost nothing about the quality of what's inside.

My standard at Magnolia is simple enough to state in one sentence: I want to know what human trial data exists, what the regulatory status is, and what we'll monitor to catch problems early. If a compound can't clear those three questions, it doesn't belong in a clinic. That standard has meant declining to offer things patients have specifically come in asking about, and those are not always comfortable conversations. I'd rather have the uncomfortable conversation.

What This Means If You're Already Taking One

Practically speaking, understanding that your medication is a peptide should change how you think about a few things.

It explains why you inject it. Peptides are chains of amino acids, and your digestive tract is built specifically to dismantle chains of amino acids. Swallow one and your stomach treats it as food. Subcutaneous injection bypasses that problem entirely, which is why nearly every peptide medication is given by needle.

It explains the titration schedule. You start low and step up over weeks not because anyone is being cautious for its own sake, but because these compounds act on receptors in your gut and brain, and giving those systems time to adapt is what separates a tolerable ramp-up from a miserable one. Patients who push their dose faster than the schedule tend to end up nauseated and discouraged.

And it explains why supervision is not optional. We run labs before starting and at intervals afterward. We watch for muscle loss, because rapid weight reduction takes lean mass along with fat unless you're deliberately protecting it with protein intake and resistance training. We ask about gallbladder symptoms. We check in on how you're actually eating, because appetite suppression can quietly slide into inadequate nutrition. If you want the fuller version of how we structure that process, our guide to physician-supervised GLP-1 weight loss in DFW walks through it, and our semaglutide program page covers what treatment looks like week to week.

Here in Southlake I see a lot of patients in their forties and fifties who are juggling work, kids' schedules, and the general chaos of a DFW summer, and who want the medication to do the work on its own. It won't, entirely. It's a powerful signal that makes the behavioral part achievable rather than a daily battle of willpower. That's a genuinely different thing from a shortcut, and patients who understand the distinction tend to do better over the long run.

So the next time someone tells you peptide therapy sounds like something from the shadier corner of medicine, you'll know the category includes insulin, and it includes the medication that lowered major cardiovascular events by a fifth in a trial of more than seventeen thousand people. The label isn't the useful question. What the evidence shows, and who's monitoring you while you take it, is where the real answer lives. If you're on a GLP-1 medication or thinking about starting one, that's the conversation I'd want to have with you at Magnolia Functional Wellness here in Southlake.